CRBP vs. CELC, STTK, SLDB, IMMP, DNTH, COGT, WVE, ACRV, STOK, and PRQR
Should you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Celcuity (CELC), Shattuck Labs (STTK), Solid Biosciences (SLDB), Immutep (IMMP), Dianthus Therapeutics (DNTH), Cogent Biosciences (COGT), Wave Life Sciences (WVE), Acrivon Therapeutics (ACRV), Stoke Therapeutics (STOK), and ProQR Therapeutics (PRQR). These companies are all part of the "medical" sector.
Celcuity (NASDAQ:CELC) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, community ranking, institutional ownership and profitability.
63.3% of Celcuity shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 20.3% of Celcuity shares are held by company insiders. Comparatively, 4.0% of Corbus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Corbus Pharmaceuticals received 104 more outperform votes than Celcuity when rated by MarketBeat users. However, 66.87% of users gave Celcuity an outperform vote while only 66.41% of users gave Corbus Pharmaceuticals an outperform vote.
Corbus Pharmaceuticals' return on equity of -61.66% beat Celcuity's return on equity.
In the previous week, Corbus Pharmaceuticals had 4 more articles in the media than Celcuity. MarketBeat recorded 7 mentions for Corbus Pharmaceuticals and 3 mentions for Celcuity. Corbus Pharmaceuticals' average media sentiment score of 1.43 beat Celcuity's score of 0.52 indicating that Celcuity is being referred to more favorably in the media.
Celcuity has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.46, indicating that its share price is 146% more volatile than the S&P 500.
Corbus Pharmaceuticals has higher revenue and earnings than Celcuity. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks.
Celcuity presently has a consensus target price of $29.50, indicating a potential upside of 94.59%. Corbus Pharmaceuticals has a consensus target price of $61.00, indicating a potential upside of 42.89%. Given Corbus Pharmaceuticals' higher probable upside, equities research analysts clearly believe Celcuity is more favorable than Corbus Pharmaceuticals.
Summary
Celcuity beats Corbus Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get Corbus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corbus Pharmaceuticals Competitors List
Related Companies and Tools
